1531955617321078786

NOW ENROLLING: Gamida Cell’s Phase 1/2 study evaluating cryopreserved formulation of #GDA-201, a readily available NK cell therapy candidate for the treatment of #follicularlymphoma and #diffuselargeBcelllymphoma. https://t.co/LpaUkxx4ci

#GamidaCellTherapy
#NAMenabled
#LRF
#LLS https://t.co/sLNXV24JKW

Send us a message